Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Inhibrx Biosciences, Inc
University of Wisconsin, Madison
Eastern Cooperative Oncology Group
Emory University
University of California, San Diego
Emory University
University of California, San Diego
VLP Therapeutics
Inhibrx Biosciences, Inc
Nanobiotix
M.D. Anderson Cancer Center
Sanford Health
University of California, San Diego
National Cancer Institute (NCI)
Celldex Therapeutics